Atlas Trials

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Clinical trial NCT03610490 · TERMINATED

Trial details

NCT number
NCT03610490
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Malignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian CarcinomaMetastatic Pancreatic Ductal AdenocarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent High Grade Ovarian Serous AdenocarcinomaRecurrent Ovarian CarcinosarcomaRefractory Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8
Start date
2018-10-16
Primary completion
2024-08-21
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.